We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
-2.07%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$19.3B
AUM Growth
-$803M
Cap. Flow
+$159M
Cap. Flow %
0.82%
Top 10 Hldgs %
30.79%
Holding
732
New
52
Increased
325
Reduced
233
Closed
41

Top Buys

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$78.3M
2
NEE icon
NextEra Energy
NEE
+$57M
3
NVDA icon
NVIDIA
NVDA
+$48M
4
BABA icon
Alibaba
BABA
+$43.4M
5
AAPL icon
Apple
AAPL
+$39M

Top Sells

Rank Stock Value
1
NU icon
Nu Holdings
NU
+$87.5M
2
RVMD icon
Revolution Medicines
RVMD
+$45.5M
3
ABT icon
Abbott
ABT
+$44.5M
4
JPM icon
JPMorgan Chase
JPM
+$44.3M
5
IQV icon
IQVIA
IQV
+$43M

Sector Composition

Rank Sector Weight
1 Technology 32.73%
2 Healthcare 27.11%
3 Financials 9.44%
4 Consumer Discretionary 7.72%
5 Communication Services 7.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CEG icon
301
Constellation Energy
CEG
$93.6B
$8.78M 0.05%
31,452
+1,511
+5% +$459K
MTZ icon
302
MasTec
MTZ
$27.8B
$8.77M 0.05%
27,272
-27,126
-50% -$7.34M
KMI icon
303
Kinder Morgan
KMI
$72B
$8.75M 0.05%
261,027
+7,964
+3% +$249K
O icon
304
Realty Income
O
$60.6B
$8.72M 0.05%
142,512
+74,253
+109% +$4.65M
EYPT icon
305
EyePoint Inc
EYPT
$1.09B
$8.69M 0.05%
674,395
LEGN icon
306
Legend Biotech
LEGN
$4.55B
$8.51M 0.04%
470,292
+208,477
+80% +$3.97M
MAZE
307
Maze Therapeutics
MAZE
$1.62B
$8.3M 0.04%
+278,167
New +$12.3M
NRIX icon
308
Nurix Therapeutics
NRIX
$2.44B
$8.28M 0.04%
534,259
ALGN icon
309
Align Technology
ALGN
$12.7B
$8.26M 0.04%
48,204
GH icon
310
Guardant Health
GH
$20.2B
$8.24M 0.04%
89,216
-59,190
-40% -$5.94M
OC icon
311
Owens Corning
OC
$11.3B
$8.19M 0.04%
75,662
+9,417
+14% +$1.12M
IMCR icon
312
Immunocore
IMCR
$1.75B
$8.13M 0.04%
269,729
FDX icon
313
FedEx
FDX
$75.2B
$8.11M 0.04%
22,772
+101
+0.4% +$35.1K
BVN icon
314
Compañía de Minas Buenaventura
BVN
$7.94B
$8.07M 0.04%
224,000
-56,000
-20% -$2.02M
ORA icon
315
Ormat Technologies
ORA
$6.46B
$8.06M 0.04%
71,988
SRE icon
316
Sempra
SRE
$59.2B
$8.04M 0.04%
82,751
-1,374
-2% -$126K
OCUL icon
317
Ocular Therapeutix
OCUL
$1.96B
$8.04M 0.04%
949,216
+107,614
+13% +$1.03M
URI icon
318
United Rentals
URI
$63.5B
$8.01M 0.04%
10,992
+711
+7% +$597K
EME icon
319
Emcor
EME
$33.8B
$7.87M 0.04%
10,664
-2,791
-21% -$2.03M
TTEK icon
320
Tetra Tech
TTEK
$7.92B
$7.81M 0.04%
259,365
+35,170
+16% +$1.24M
FCN icon
321
FTI Consulting
FCN
$4.68B
$7.73M 0.04%
43,723
-1,839
-4% -$314K
PEG icon
322
Public Service Enterprise Group
PEG
$38.6B
$7.73M 0.04%
95,454
+14,154
+17% +$1.16M
PHM icon
323
Pultegroup
PHM
$23.7B
$7.7M 0.04%
65,459
-36,242
-36% -$4.64M
WAT icon
324
Waters Corp
WAT
$36.1B
$7.67M 0.04%
25,766
+19,232
+294% +$6.58M
WCN
325
Waste Connections
WCN
$42.8B
$7.64M 0.04%
47,116
-7,840
-14% -$1.31M

Similar funds

Candriam SCA's Q1 2026 Portfolio in Review

As of Q1 2026, Candriam SCA held 732 positions worth $19.3B, down 4% from $20.1B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Candriam SCA's Q1 2026 filing shows 52 new, 325 increased, 233 reduced and 41 closed positions. Its largest new stake was Service Corp International: 360,195 shares worth $29.7M. The largest sale was Nu Holdings, an estimated $87.5M.

By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 34% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q1 2026 buy was Service Corp International: 360,195 shares worth $29.7M.
  • Candriam SCA added most to KLA in Q1 2026, an estimated $78.3M increase.
  • Candriam SCA's biggest Q1 2026 reduction was Nu Holdings, cutting an estimated $87.5M.
  • Candriam SCA fully exited Banco Macro in Q1 2026, selling an estimated $25.6M.
  • Candriam SCA's ten largest holdings make up 31% of its $19.3B portfolio in Q1 2026.
  • Candriam SCA opened 52 new positions and closed 41 in Q1 2026.
  • Candriam SCA's portfolio value fell 4% quarter-over-quarter to $19.3B.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.